Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 30;11(11):3090.
doi: 10.3390/jcm11113090.

Evolving Indications of Transcatheter Aortic Valve Replacement-Where Are We Now, and Where Are We Going

Jules Mesnier  1 , Vassili Panagides  1 , Jorge Nuche  1 , Josep Rodés-Cabau  1
Affiliations
Review

Evolving Indications of Transcatheter Aortic Valve Replacement-Where Are We Now, and Where Are We Going

Jules Mesnier et al. J Clin Med. .

Abstract

Indications for transcatheter aortic valve replacement (TAVR) have steadily increased over the last decade since the first trials including inoperable or very high risk patients. Thus, TAVR is now the most common treatment of aortic valve stenosis in elderly patients (vs. surgical aortic valve replacement -SAVR-). In this review, we summarize the current indications of TAVR and explore future directions in which TAVR indications can expand.

Keywords: aortic regurgitation; aortic stenosis; bicuspid valve; moderate aortic stenosis; transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

Rodés-Cabau has received institutional research grants from Edwards Lifesciences, Medtronic, Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

Figure 1
Figure 1
Clinical characteristics in favor of surgical or transcatheter aortic valve replacement. CAD, coronary artery disease; TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement.
Figure 2
Figure 2
Future direction in TAVR indication; AS, aortic stenosis; TF, transfemoral.
Figure 3
Figure 3
EXPAND TAVR II trial study design; AS, aortic stenosis; BAV, bicuspid aortic valve; HF, heart failure; OMT, optimal medical therapy; TAVR, transcatheter aortic valve replacement; TF, transfemoral.
See this image and copyright information in PMC

References

    1. Cribier A., Eltchaninoff H., Tron C., Bauer F., Agatiello C., Sebagh L., Bash A., Nusimovici D., Litzler P.Y., Bessou J.-P., et al. Early experience with percutaneous transcatheter implantation of heart valve pros-thesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J. Am. Coll. Cardiol. 2004;43:698–703. doi: 10.1016/j.jacc.2003.11.026. - DOI - PubMed
    1. Smith C.R., Leon M.B., Mack M.J., Miller D.C., Moses J.W., Svensson L.G., Tuzcu E.M., Webb J.G., Fontana G.P., Makkar R.R., et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. N. Engl. J. Med. 2011;364:2187–2198. doi: 10.1056/NEJMoa1103510. - DOI - PubMed
    1. Adams D.H., Popma J.J., Reardon M.J., Yakubov S.J., Coselli J.S., Deeb G.M., Gleason T.G., Buchbinder M., Hermiller J., Jr., Kleiman N.S., et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. N. Engl. J. Med. 2014;370:1790–1798. doi: 10.1056/NEJMoa1400590. - DOI - PubMed
    1. Leon M.B., Smith C.R., Mack M.J., Makkar R.R., Svensson L.G., Kodali S.K., Thourani V.H., Tuzcu E.M., Miller D.C., Herrmann H.C., et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N. Engl. J. Med. 2016;374:1609–1620. doi: 10.1056/NEJMoa1514616. - DOI - PubMed
    1. Reardon M.J., Van Mieghem N.M., Popma J.J., Kleiman N.S., Søndergaard L., Mumtaz M., Adams D.H., Deeb G.M., Maini B., Gada H., et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N. Engl. J. Med. 2017;376:1321–1331. doi: 10.1056/NEJMoa1700456. - DOI - PubMed

LinkOut - more resources